SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

• Published in: Cardiovascular diabetology Vol. 18; no. 1; pp. 15 - 13
• Main Authors: Li, Chenguang, Zhang, Jie, Xue, Mei, Li, Xiaoyu, Han, Fei, Liu, Xiangyang, Xu, Linxin, Lu, Yunhong, Cheng, Ying, Li, Ting, Yu, Xiaochen, Sun, Bei, Chen, Liming
• Format: Journal Article
• Language: English
• Published: England BioMed Central 02.02.2019; BMC
• Subjects: Animals; Antidiabetics; Antioxidant Response Elements; Antioxidants; Antioxidants - pharmacology; Apoptosis; Benzhydryl Compounds - pharmacology; Cardiomyopathy; Cardiovascular disease; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Diabetic Cardiomyopathies - etiology; Diabetic Cardiomyopathies - metabolism; Diabetic Cardiomyopathies - physiopathology; Diabetic Cardiomyopathies - prevention & control; Disease Models, Animal; Echocardiography; Empagliflozin; Fibrosis; Glucose; Glucosides - pharmacology; Growth factors; Heart; Hyperglycemia; Immunohistochemistry; Insulin; Mice, Inbred C57BL; Myocardial fibrosis; Myocardium; Myocardium - metabolism; Myocardium - pathology; NF-E2-Related Factor 2 - metabolism; Original Investigation; Oxidants; Oxidative stress; Oxidative Stress - drug effects; Phosphorylation; Rodents; SGLT2; Signal Transduction - drug effects; Smad protein; Smad Proteins - metabolism; Sodium; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 - metabolism; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Structure-function relationships; Transforming growth factor; Transforming Growth Factor beta1 - metabolism; Transforming growth factor-b; Type 2 diabetes mellitus; Uric acid; Ventricular Function, Left - drug effects; Ventricular Remodeling - drug effects; Beijing China; China; Empagliflozin; Oxidative stress; Myocardial fibrosis; Type 2 diabetes mellitus; SGLT2

Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reported to improve glycaemic control in patients with type 2 diabetes in an insulin-independent m...